for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Innate Pharma SA

IPH.PA

Latest Trade

5.57EUR

Change

-0.10(-1.76%)

Volume

190,665

Today's Range

5.53

 - 

5.79

52 Week Range

5.24

 - 

8.24

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
5.67
Open
5.71
Volume
190,665
3M AVG Volume
6.33
Today's High
5.79
Today's Low
5.53
52 Week High
8.24
52 Week Low
5.24
Shares Out (MIL)
64.03
Market Cap (MIL)
445.44
Forward P/E
-34.96
Dividend (Yield %)
--

Next Event

Innate Pharma SA Annual Shareholders Meeting

Latest Developments

More

Innate Pharma Highlights FDA-Approved Lumoxiti

Innate Pharma Reports End-Sept Cash At 215.2 Million Euros

Innate Pharma Announces Preclinical Data Presentations At SITC 2019

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Innate Pharma SA

Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.

Industry

Biotechnology & Drugs

Contact Info

117 avenue de Luminy, Bp 30191

+33.4.30303030

http://www.innate-pharma.com

Executive Leadership

Herve Brailly

Chairman of the Supervisory Board

Mondher Mahjoubi

Chairman of the Executive Board, Chief Executive Officer

Irina Staatz-Granzer

Independent Vice Chairman of the Supervisory Board

Laure-Hélène Mercier

Chief Financial Officer, Executive Vice President, Member of the Executive Committee

Yannis Morel

Executive Vice President Products Portfolio Strategy & Business Development, Member of the Executive Board

Key Stats

1.71 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.1K

2017

0.0K

2018

0.1K

2019(E)

0.1K
EPS (EUR)

2016

0.230

2017

-0.890

2018

0.050

2019(E)

-0.162
Price To Earnings (TTM)
10.88
Price To Sales (TTM)
3.89
Price To Book (MRQ)
2.00
Price To Cash Flow (TTM)
9.98
Total Debt To Equity (MRQ)
18.09
LT Debt To Equity (MRQ)
5.07
Return on Investment (TTM)
15.59
Return on Equity (TTM)
11.23

Latest News

Latest News

BRIEF-Innate Pharma Announces Updated Results On IPH4102

* ANNOUNCED ON MONDAY UPDATED RESULTS THAT SUPPORT ADVANCEMENT OF IPH4102 IN REFRACTORY SÉZARY SYNDROME

AstraZeneca digs deeper into cancer with Innate stake

AstraZeneca <AZN.L> is ploughing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma <IPH.PA>, which includes the British group buying a 9.8 percent stake in the French biotech company.

AstraZeneca to buy 9.8 pct stake in France's Innate Pharma

British drugmaker AstraZeneca will buy a newly-issued equity stake of 9.8 percent in smaller French peer Innate Pharma, strengthening its presence in the field of immuno-oncology.

BRIEF-Innate Pharma: Phase II Results From Monalizumab/Cetuximab In Head And Neck Cancer

* INNATE PHARMA ANNOUNCED ON SATURDAY PHASE II RESULTS FROM MONALIZUMAB/CETUXIMAB IN HEAD AND NECK CANCER

BRIEF-Innate Pharma Publishes Phase 1 IPH4102 Results

* REPORTED ON SATURDAY IPH4102 PHASE 1 RESULTS IN ADVANCED CUTEANOUS T CELL LYMPHOMA

BRIEF-Innate Pharma Announces Promising Anti-Tumor Activity Of Monalizumab With Cetuximab In SCCHN

* PROMISING ANTI-TUMOR ACTIVITY OF MONALIZUMAB WITH CETUXIMAB IN SCCHN

BRIEF-Reg-Innate Pharma Aacr 2018, New Preclinical Data Further Support Ongoing Programs

* REG-INNATE PHARMA : AACR 2018, NEW PRECLINICAL DATA FURTHER SUPPORT ONGOING PROGRAMS Source text for Eikon: Further company coverage:

BRIEF-Innate Pharma Announces Its Partner Medimmune Expands Colorectal Cancer Patient Cohort In A Phase I Trial

* INNATE PHARMA SA - PARTNER MEDIMMUNE EXPANDS COLORECTAL CANCER PATIENT COHORT IN ONGOING PHASE I TRIAL EVALUATING MONALIZUMAB IN COMBINATION WITH IMFINZI® (DURVALUMAB) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Innate Pharma Expands mCRC Cohort In Phase I Trial Evaluating Monalizumab With Imfinzi

* REG-INNATE PHARMA : EXPANSION OF MCRC COHORT IN PHASE I TRIAL EVALUATING MONALIZUMAB WITH IMFINZI

BRIEF-Innate Pharma FY Net Results Swings To Loss Of 48.4 Million Euros

* FY REVENUE AND OTHER INCOME EUR 44.0 MILLION VERSUS EUR 65.7 MILLION YEAR AGO

BRIEF-Innate Pharma Appoints Jean-Yves Blay To Its Supervisory Board

* INNATE PHARMA SA - JEAN-YVES BLAY APPOINTED TO INNATE PHARMA SUPERVISORY BOARD Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Innate Pharma And Medimmune Enter Clinical Trial Collaboration

* INNATE PHARMA AND MEDIMMUNE ENTER CLINICAL TRIAL COLLABORATION

BRIEF-Eric Vivier Joins Innate Pharma As Chief Scientific Officer

* REG-WORLD RENOWNED IMMUNOLOGIST, PROFESSOR ERIC VIVIER, JOINS INNATE PHARMA AS CHIEF SCIENTIFIC OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Innate Pharma provides an update on lirilumab

* LIRILUMAB CONTINUES TO BE WELL-TOLERATED IN MONOTHERAPY AND IN COMBINATION ACROSS MULTIPLE TUMOR INDICATIONS

BRIEF-Innate Pharma Q3 revenue up at 12.4 million euros

* Q3 REVENUE EUR 12.4 MILLION VERSUS EUR 11.2 MILLION YEAR AGO

BRIEF-Innate Pharma reports IPH4102 final results of the dose-escalation part of the phase I study

* IPH4102: FINAL RESULTS OF THE DOSE-ESCALATION PART OF THE PHASE I STUDY

BRIEF-Innate Pharma H1 operating loss widens to 18.2 million euros

* CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS() FOR COMPANY AMOUNTED TO EUR 204.1M (MILLION EUROS) AS OF JUNE 30, 2017

BRIEF-New preclinical data further strengthen rationale of IPH5401 and Monalizumab

* REG-INNATE PHARMA : NEW PRECLINICAL DATA FURTHER STRENGTHEN THE RATIONALE OF IPH5401 AND MONALIZUMAB

BRIEF-Innate Pharma issues 3,343,748 ordinary shares

* REG-ISSUANCE BY INNATE PHARMA OF 3,343,748 ORDINARY SHARES TO NOVO NORDISK A/S IN CONSIDERATION FOR RIGHTS IN ANTI-C5AR

BRIEF-Innate Pharma to list 3,343,748 new ordinary shares - Euronext

* INNATE PHARMA TO LIST 3,343,748 NEW ORDINARY SHARES AS OF JULY 17 FOLLOWING CAPITAL INCREASE BY CONTRIBUTION FURTHER COMPANY COVERAGE: (Gdynia Newsroom:)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up